Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Morphosys Ag ADR (MOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,135,702
  • Shares Outstanding, K 126,236
  • Annual Sales, $ 90,280 K
  • Annual Income, $ -66,340 K
  • 60-Month Beta 1.12
  • Price/Sales 34.86
  • Price/Cash Flow N/A
  • Price/Book 5.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.27
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.30
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -17.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.04 +7.03%
on 06/06/19
27.15 -9.17%
on 05/22/19
-1.34 (-5.15%)
since 05/17/19
3-Month
22.46 +9.80%
on 03/28/19
27.15 -9.17%
on 05/22/19
+0.65 (+2.71%)
since 03/15/19
52-Week
21.75 +13.38%
on 10/26/18
35.90 -31.31%
on 07/24/18
-4.61 (-15.75%)
since 06/15/18

Most Recent Stories

More News
MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 14, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) announced today that its licensee Janssen Research & Development,...

MOR : 24.66 (-0.72%)
MorphoSys AG Reports Outcome of Annual General Meeting 2019

All Resolutions Proposed by the Company's Management Approved

MOR : 24.66 (-0.72%)
MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 16, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR):

MOR : 24.66 (-0.72%)
MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 16, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today announced results from the primary analysis (cut-off date November...

MOR : 24.66 (-0.72%)
MorphoSys AG to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 8, 2019 / MorphoSys AG (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 2:00 PM Eastern Time.

MOR : 24.66 (-0.72%)
MorphoSys AG Reports First Quarter 2019 Results

MOR : 24.66 (-0.72%)
NVS : 89.76 (+0.27%)
Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; Nasdaq: MOR) will publish its first three months' 2019 results on

MOR : 24.66 (-0.72%)
MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma

PLANEGG/MUNICH, GERMANY and SHANGHAI, CHINA / ACCESSWIRE / April 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical...

MOR : 24.66 (-0.72%)
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

Mechelen, Belgium and Planegg/Munich, Germany; 23 April 2019; 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Novartis Pharma...

MOR : 24.66 (-0.72%)
GLPG : 121.00 (-0.15%)
MorphoSys Nominates New Candidate for Supervisory Board

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 10, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that it has published its agenda for the Company's ordinary...

MOR : 24.66 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade MOR with:

Business Summary

MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG...

See More

Key Turning Points

2nd Resistance Point 24.99
1st Resistance Point 24.92
Last Price 24.66
1st Support Level 24.72
2nd Support Level 24.59

See More

52-Week High 35.90
Fibonacci 61.8% 30.49
Fibonacci 50% 28.83
Fibonacci 38.2% 27.16
Last Price 24.66
52-Week Low 21.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar